New GOLD guidelines, strategies, and challenges highlighted the key developments for primary care physicians in 2019.
Depression, Anxiety Underrecognized and Undertreated in COPD, Increasing Disease Burden
A new analysis reveals significant gaps in diagnosis of and treatment for psychiatric disorders in adults with COPD and calls for larger, longitudinal studies.
Omlyclo Gains FDA Approval as Interchangeable Omalizumab Biosimilar: Daily Dose
Your daily dose of the clinical news you may have missed.
Dupilumab Found Beneficial in COPD with Type 2 Inflammation: Daily Dose
FDA Approves Omlyclo as First Interchangeable Omalizumab Biosimilar
Omlyclo is indicated for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria.
Dupilumab Shows Efficacy and Safety in COPD With Type 2 Inflammation: AAAAI 2025
Investigators concluded that dupilumab reduced exacerbation rates, improved lung function, and decreased systemic corticosteroid use in patients with COPD driven by type 2 inflammation.
5 Drug Classes Linked to Increased Fall Risk Among Adults with COPD Near End of Life